Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S95-S101

  Schito, Marco ^a   Maeurer, Markus ^b,c   Kim, Peter ^d   Hanna, Debra ^a   Zumla, Alimuddin ^e,f,g  

^a CRITICAL PATH INSTITUTE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Division of Infection and Immunity   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

drug resistance; new treatment regimens; research; resource limited settings; Tuberculosis

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; ISONIAZID; PRETOMANID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HUMAN; INFECTION CONTROL; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION; DRUG DEVELOPMENT; DRUG EFFECTS; ECONOMICS; GENETICS; HEALTH; HEALTH CARE PLANNING; MEDICAL RESEARCH; MOLECULAR DIAGNOSIS; POINT OF CARE SYSTEM; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; GLOBAL HEALTH; HEALTH RESOURCES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84943428817     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ608     Document Type: Article

References (41)

1. Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulm Med 2013; 19:229-37.
2. Bates M, Mudenda V, Shibemba A, et al. Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. Lancet Infect Dis 2015; 15:544-51.
3. UNITAID. Tuberculosis: diagnostic technology and market landscape. 3rd ed. Geneva, Switzerland: WHO, 2014:1-42.
4. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 282:677-86.
5. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119:183-201.
6. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014. Available at: http://www.who.int/tb/publications/global-report/en/. Accessed 16 February 2015.
7. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54:579-81.
8. Klopper M, Warren RM, Hayes C, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2013; 19:449-55.
9. Shah NS, Brust J, Mathema B, et al. Majority of XDR TB cases are due to transmission in a high-HIV-prevalence setting [Abstract 92]. In: Abstracts and Electronic Posters for the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015.
10. Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2011; 44:106-10.
11. Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014; 46:279-86.
12. Song T, Park Y, Shamputa IC, et al. Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the ' subunit of RNA polymerase. Mol Microbiol 2014; 91:1106-19.
13. Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013; 29:160-9.
14. Lin PL, Coleman T, Carney JPJ, et al. Radiologic responses in cynomolgus macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013; 57:4237-44.
15. Merker M, Kohl TA, Roetzer A, et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 2013; 8:e82551.
16. World Health Organization. Strategic and Technical Advisory Group for Tuberculosis. Report of the 10th meeting. WHO/HTM/TB/2010.18. Geneva, Switzerland: WHO, 2010. Available at: http://www. who.int/entity/tb/advisory-bodies/stag-tb-report-2010.pdfua=1. Accessed 16 February 2015.
17. World Health Organization. Policy update: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. WHO/HTM/TB/2013.16. Geneva, Switzerland: WHO, 2013. Available at: http://www.who.int/iris/bitstream/10665/112472/1/9789241506335-eng.pdfua=1. Accessed 16 February 2015.
18. Yoon C, Cattamanchi A, Davis JL, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One 2012; 7:e48599.
19. Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One 2013; 8:e65421.
20. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. WHO/HTM/TB/2014.18. Geneva, Switzerland: WHO, 2014. Available at: http://apps.who.int/iris/bitstream/10665/135617/1/WHO-HTM-tuberculosis-2014.18-eng.pdfua=1&ua=1. Accessed 16 February 2015.
21. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444(suppl 1):49-57.
22. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA 2009; 106:7672-7.
23. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacincontaining regimen for treating tuberculosis. N Engl J Med 2014; 371:1588-98.
24. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371:1599-608.
25. Gillespie SH, Crook AM, McHugh TD, et al. REMoxTB: a double-blind randomized controlled non-inferiority phase 3 trial of two four-month moxifloxacin regimens for the treatment of drug-sensitive tuberculosis [Abstract L-1062]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014.
26. Drug Pipeline.Working Group on New TB Drugs. StopTB Partnership. Available at: http://www.newtbdrugs.org/pipeline.php. Accessed 16 February 2015.
27. Boeree MJ, Diacon AH, Dawson R, et al. A dose ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191:1058-65.
28. Boeree MJ, Hoelscher M. High-dose rifampin, SQ109 and moxifloxacin for treating TB: The PanACEA MAMS-TB trial [abstract 95LB]. In: Abstracts and Electronic Posters for the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015.
29. Romero K, Clay R, Hanna D. Strategic regulatory evaluation and endorsement of the hollow fiber tuberculosis system as a novel drug development tool. Clin Infect Dis 2015; 61(suppl 1):S5-9.
30. Zhang L, Pang Y, Yu X, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection 2014; 42:705-11.
31. Gillespie SH, Basu S, Dickens AL, O'Sullivan DM, McHugh TD. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 2005; 56:344-8.
32. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Executive board. In: 134th session. EB134/12. Geneva, Switzerland: WHO, 2013.
33. Fauci AS, Folkers GK, Marston HD. Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. Clin Infect Dis 2014; 59(suppl 2):S80-4.
34. Fauci AS, Marston HD. Ending AIDS-is an HIV vaccine necessary N Engl J Med 2014; 370:495-8.
35. Maeurer M, Zumla A. The host battles drug-resistant tuberculosis. Sci Transl Med 2014; 6:1-3.
36. Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014; 511:99-103.
37. Friedland JS. Targeting the inflammatory response in tuberculosis. N Engl J Med 2014; 371:1354-6.
38. Zumla A, Maeurer M, Host-Directed Therapies Network. Towards hostdirected therapies for tuberculosis. Nat Rev Drug Discov 2015; 14:511-2.
39. Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013; 13:436-48.
40. Skowroski M, Zozuliska-Ziókiewicz D, Barinow-Wojewódzki A. Tuberculosis and diabetes mellitus-an underappreciated association. Arch Med Sci 2014; 10:1019-27.
41. World Hunger Education Service. World hunger and poverty facts and statistics, 2012. Available at: http://worldhunger.org/articles/Learn/world%20hunger%20facts%202002.htm. Accessed 16 February 2015.